Inventor · disambiguated record
Rob N. De Jong
Also filed as: DE JONG ROB · DE JONG ROB N
17 granted patents·31 pending applications·91 citations·filing 2009–2025
94Inventor score
Top patents by PatentIndex Score
48 records- 0197US12049512B2Antibody variants and uses thereofGENMAB BV·Filed 2020·Granted Jul 30, 2024·5 cites·17 claims
- 0293US10759867B2Antibody variants and uses thereofPARREN PAUL·Filed 2012·Granted Sep 1, 2020·14 cites·6 claims
- 0392US10479835B2Agent, uses and methods for treatmentH LUNDBECK AS·Filed 2016·Granted Nov 19, 2019·4 cites·16 claims
- 0492US10428147B2Anti-sortilin antibodies, uses and methods for treatmentH LUNDBECK AS·Filed 2016·Granted Oct 1, 2019·4 cites·7 claims
- 0591US11180572B2Dimeric protein with triple mutationsGENMAB BV·Filed 2013·Granted Nov 23, 2021·12 cites·45 claims
- 0690US10889650B2Agent, uses and methods for treatmentH LUNDBECK AS·Filed 2019·Granted Jan 12, 2021·2 cites·19 claims
- 0790US10201607B2Antibodies binding AXLGENMAB AS·Filed 2018·Granted Feb 12, 2019·7 cites·28 claims
- 0890US9714297B2Human antibodies against tissue factor and methods of use thereofGENMAB AS·Filed 2015·Granted Jul 25, 2017·9 cites·29 claims
- 0990US9150658B2Human antibodies against tissue factor and methods of use thereofVERPLOEGEN SANDRA·Filed 2009·Granted Oct 6, 2015·20 cites·43 claims
- 1089US10765743B2Antibodies binding AXLGENMAB AS·Filed 2019·Granted Sep 8, 2020·3 cites·46 claims
- 1188US11548950B2Agent, uses and methods for treatmentH LUNDBECK AS·Filed 2020·Granted Jan 10, 2023·1 cites·19 claims
- 1287US10500276B2Antibodies binding AXLGENMAB AS·Filed 2019·Granted Dec 10, 2019·4 cites·35 claims
- 1386US10512688B2Antibodies binding AXLGENMAB AS·Filed 2015·Granted Dec 24, 2019·4 cites·8 claims
- 1485US2025223374A1Antibody variants and uses thereofGENMAB BV·Filed 2024·Application pending·0 cites
- 1584US12331123B2Agent, uses and methods for treatmentH LUNDBECK AS·Filed 2022·Granted Jun 17, 2025·0 cites·22 claims
- 1684US2025043018A1Antibody variants and uses thereofPARREN PAUL·Filed 2024·Application pending·0 cites
- 1782US2025277040A1Agent, uses and methods for treatmentH LUNDBECK AS·Filed 2025·Application pending·0 cites
- 1882US2023416403A1Human antibodies against tissue factor and methods of use thereofGENMAB AS·Filed 2022·Application pending·0 cites
- 1979US2025340669A1Human antibodies against tissue factor and methods of use thereofGENMAB AS·Filed 2025·Application pending·0 cites
- 2076US12247065B2Method for producing a controlled mixture of two or more different antibodiesGENMAB AS·Filed 2019·Granted Mar 11, 2025·1 cites·36 claims
- 2176US2025145720A1Human igg1 fc region variants and uses thereofGENMAB BV·Filed 2024·Application pending·0 cites
- 2276US2020171152A1Antibodies binding axlGENMAB AS·Filed 2019·Application pending·0 cites
- 2376US2022411522A1Anti-death receptor antibodies and methods of use thereofGENMAB BV·Filed 2022·Application pending·0 cites
- 2475US12173076B2Polypeptide variants and uses thereofGENMAB BV·Filed 2018·Granted Dec 24, 2024·1 cites·15 claims
- 2575US2023321261A1Axl-specific antibody-drug conjugates for cancer treatmentGENMAB AS·Filed 2022·Application pending·0 cites
- 2673US2025326854A1Polypeptide variants and uses thereofGENMAB BV·Filed 2024·Application pending·0 cites
- 2773US2023212301A1Antibodies capable of binding to cd27, variants thereof and uses thereofGENMAB BV·Filed 2022·Application pending·0 cites
- 2872US2023109496A1Antibodies capable of binding to cd27, variants thereof and uses thereofGENMAB BV·Filed 2022·Application pending·0 cites
- 2971US2025289900A1Antibodies capable of binding to cd27, variants thereof and uses thereofGENMAB AS·Filed 2025·Application pending·0 cites
- 3071US2025289899A1Antibodies capable of binding to cd27, variants thereof and uses thereofGENMAB AS·Filed 2025·Application pending·0 cites
- 3169US2021171657A1Human antibodies against tissue factor and methods of use thereofGENMAB AS·Filed 2020·Application pending·0 cites
- 3266US2023107363A1Polypeptide variants and uses thereofGENMAB BV·Filed 2022·Application pending·0 cites
- 3365US2020397913A1Axl-specific antibody-drug conjugates for cancer treatmentGENMAB AS·Filed 2020·Application pending·0 cites
- 3464US2022332801A1Antibodies and methods of use thereof in treatment of infectious diseaseGENMAB BV·Filed 2021·Application pending·0 cites
- 3564US2019169311A1Human Antibodies Against Tissue Factor and Methods of Use ThereofGENMAB AS·Filed 2018·Application pending·0 cites
- 3662US2019022243A1Axl-specific antibody-drug conjugates for cancer treatmentGENMAB AS·Filed 2017·Application pending·0 cites
- 3761US2018044431A1Human antibodies against tissue factor and methods of use thereofGENMAB AS·Filed 2017·Application pending·0 cites
- 3861US2019202926A1Anti-death receptor antibodies and methods of use thereofGENMAB BV·Filed 2016·Application pending·0 cites
- 3960US2018326084A1Axl-specific antibody-drug conjugates for cancer treatmentGENMAB AS·Filed 2016·Application pending·0 cites
- 4059US2025325643A1Binding agents capable of binding to cd27 in combination therapyGENMAB AS·Filed 2023·Application pending·0 cites
- 4152US2015353636A1Human igg1 fc region variants and uses thereofGENMAB BV·Filed 2013·Application pending·0 cites
- 4251US2021230301A1Dimeric protein with triple mutationsGENMAB BV·Filed 2020·Application pending·0 cites
- 4350US2020123237A1Antibodies and methods of use thereof in treatment of infectious diseaseGENMAB BV·Filed 2017·Application pending·0 cites
- 4449US12338289B2Antibody variant combinations and uses thereofGENMAB BV·Filed 2019·Granted Jun 24, 2025·0 cites·17 claims
- 4548US2022411529A1Antibody variant combinations and uses thereofGENMAB BV·Filed 2020·Application pending·0 cites
- 4648US2023089196A1Methods for the quantification of glycoproteinsGENMAB BV·Filed 2021·Application pending·0 cites
- 4747US2019276549A1Polypeptide variants and uses thereofGENMAB BV·Filed 2017·Application pending·0 cites
- 4844US2021107988A1Polypeptide variants and uses thereofGENMAB BV·Filed 2019·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →